Mult Scler August 2004 PMID 15327040

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.

C Vaney, M Heinzel-Gutenbrunner, P Jobin, F Tschopp, B Gattlen, U Hagen, M Schnelle, M Reif

Mentions

19
Peak: 2 in Sep 2017
across 3 sources since Sep 2017

Extended reach

117,192
potential audience

Total likes

5,831

Video views

109,005

Mentions per month

Sep 2017 – May 2019

Where it's discussed

  • Facebook15 posts
  • X / Twitter2 posts
  • YouTube2 videos

AI synopsis

What people are saying

Discussions reflect an analytical tone, with posts referencing the study's methodology and findings, such as the mention of 'no significant difference overall' and 'improvements in spasm frequency in certain patients,' showing moderate engagement. Phrases like 'reviewing the results' imply genuine interest, while the cautious tone indicates recognition of limited impact without strong endorsement or rejection.

AgreementNeither agree nor disagree

The discussions are mixed, with some acknowledging the study's findings but not expressing strong support or disagreement overall.

InterestModerate interest

Many discussions show curiosity about the efficacy and safety of the cannabis extract, indicating moderate interest.

EngagementModerate engagement

The posts engage with specifics of the study, mentioning the methodology and results, signaling active participation.

ImpactNeutral impact

The overall influence of the publication appears limited, with no signs of widespread decisive change or controversy.

Abstract in brief

  • This study tested whether an oral cannabis extract (containing THC and CBD) can help reduce spasticity in MS patients.
  • It involved 57 patients in a double-blind trial where they received either the cannabis extract or a placebo, with measures including self-reported spasms, mobility tests, and other functional assessments.
  • While no significant differences were found overall between the treatment and placebo groups, some improvements in spasm frequency and mobility were observed in patients who strictly followed the protocol, with mild side effects being more common during active treatment.]

Top posts

Most liked on X and Bluesky
森 勇一
@ymori117 · X

@drfrogger 第三の論文は、ガイドライン本文中にもありますように、参加者数が少なすぎて何も判断できません。 https://t.co/kMoLqhU3bm

May 24, 2019 · 1 like · 1 share · 7,227 followers View post →
十円龍@ワクチン接種済
@junenryu · X

RT @ymori117: @drfrogger 第三の論文は、ガイドライン本文中にもありますように、参加者数が少なすぎて何も判断できません。 https://t.co/kMoLqhU3bm

May 27, 2019 · 1 share · 956 followers View post →

All mentions

十円龍@ワクチン接種済
@junenryu · X

RT @ymori117: @drfrogger 第三の論文は、ガイドライン本文中にもありますように、参加者数が少なすぎて何も判断できません。 https://t.co/kMoLqhU3bm

May 27, 2019 · 1 share · 956 followers View post →
森 勇一
@ymori117 · X

@drfrogger 第三の論文は、ガイドライン本文中にもありますように、参加者数が少なすぎて何も判断できません。 https://t.co/kMoLqhU3bm

May 24, 2019 · 1 like · 1 share · 7,227 followers View post →